Skip to main
STAA
STAA logo

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 0%
Hold 46%
Sell 8%
Strong Sell 0%

Bulls say

Staar Surgical Co is positioned for sustained revenue growth, with projected sales increasing to $156 million in 2026, reflecting a 7% year-over-year rise driven by market growth and share gains in the Implantable Collamer lens segment. Key factors supporting this positive outlook include the potential for a faster domestic EVO launch, expanded market share in refractive error correction, and improved margins resulting in stronger earnings per share growth. The company's focus on streamlining operations and enhancing its cost structure further bolsters its ability to capture long-term growth opportunities in the global refractive market.

Bears say

The financial outlook for Staar Surgical Co appears negative due to a series of fundamental challenges impacting revenue growth. The company is facing significant risks, including elevated inventory levels from its new distributor in China, which have led to a notable revenue recognition issue and declining sales forecasts for the upcoming year. Additionally, external pressures such as soft global macroeconomic conditions, patient affordability concerns, and competition from lower-cost alternatives further contribute to a bleak growth trajectory.

STAAR Surgical (STAA) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 0% recommend Buy, 46% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 13 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.